Biological factors that impinge on Chagas disease drug development.


Francisco, AF; Jayawardhana, S; Lewis, MD; Taylor, MC; Kelly, JM; (2017) Biological factors that impinge on Chagas disease drug development. Parasitology. pp. 1-10. ISSN 0031-1820 DOI: 10.1017/S0031182017001469

Full text not available from this repository. (Request a copy)

Abstract

Chagas disease is caused by infection with the insect-transmitted protozoan Trypanosoma cruzi, and is the most important parasitic infection in Latin America. The current drugs, benznidazole and nifurtimox, are characterized by limited efficacy and toxic side-effects, and treatment failures are frequently observed. The urgent need for new therapeutic approaches is being met by a combined effort from the academic and commercial sectors, together with major input from not-for-profit drug development consortia. With the disappointing outcomes of recent clinical trials against chronic Chagas disease, it has become clear that an incomplete understanding of parasite biology and disease pathogenesis is impacting negatively on the development of more effective drugs. In addition, technical issues, including difficulties in establishing parasitological cure in both human patients and animal models, have greatly complicated the assessment of drug efficacy. Here, we outline the major questions that need to be addressed and discuss technical innovations that can be exploited to accelerate the drug development pipeline.

Item Type: Article
Faculty and Department: Faculty of Infectious and Tropical Diseases > Dept of Pathogen Molecular Biology
Research Centre: Antimicrobial Resistance Centre (AMR)
PubMed ID: 28831944
URI: http://researchonline.lshtm.ac.uk/id/eprint/4281547

Statistics


Download activity - last 12 months
Downloads since deposit
0Downloads
11Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item